CN112076322A

CN112076322A - anti-I type herpes simplex virus medicine and preparation method and application thereof

Info

Publication number: CN112076322A
Application number: CN202010963243.0A
Authority: CN
Inventors: 孙彩军; 赵锦
Original assignee: National Sun Yat Sen University
Current assignee: Sun Yat Sen University; National Sun Yat Sen University
Priority date: 2020-09-14
Filing date: 2020-09-14
Publication date: 2020-12-15

Abstract

The invention relates to a medicament for resisting I type herpes simplex virus, a preparation method and application thereof, wherein the medicament for resisting I type herpes simplex virus comprises: any one or combination of at least two of kynurenine hydroxylase genes, kynurenine hydroxylase enzymes or a metabolite quinolinic acid of the kynurenine hydroxylase enzymes. The kynurenine hydroxylase gene belongs to an interferon activating gene, and can promote the expression of IFN-beta in host cells after the kynurenine hydroxylase gene is overexpressed to generate the kynurenine hydroxylase, effectively inhibit the growth and the reproduction of HSV-1, and further protect the host cells.

Description

anti-I type herpes simplex virus medicine and preparation method and application thereof

Technical Field

The invention belongs to the field of biological medicine, and particularly relates to an anti-I type herpes simplex virus medicine, and a preparation method and application thereof.

Background

Herpes simplex type i virus is a highly contagious virus and is transmitted primarily by orooral contact and sexually, and also from infected pregnant mothers to infants. Herpes simplex virus type I infections are usually asymptomatic or associated with mild symptoms, such as cold sores and the like, and can also cause neurological disorders including keratitis and encephalitis when severe.

Currently, anti-herpes simplex virus drugs used clinically include: acyclovir and its derivatives (e.g., ganciclovir, famciclovir, valacyclovir, etc.), foscarnet, cidofovir, etc., which can alleviate clinical symptoms by inhibiting DNA synthesis of HSV, but cannot fundamentally prevent latent infection and recurrence of herpes simplex virus type i. In addition, no vaccine or drug is currently available for the prevention of new herpes simplex type i virus infections. Therefore, the type I herpes simplex virus still poses a great threat to human public health.

The type I interferon (IFN-alpha, IFN-beta) system is important for resisting the infection of the type I herpes simplex virus in the brain, and Interferon Stimulated Genes (ISGs), cholesterol-25-monooxygenase (CH25H) and a metabolite 25-hydroxycholesterol (25HC) formed by catalysis of the interferon stimulated genes can reduce the infection of the herpes simplex virus. Wherein, 25HC enhances the generation of IL-6 induced by HSV-1 infection, and 25HC has obvious antiviral and antibacterial activity. The immune response induced by the ISGs confers an enhanced antiviral state to limit viral transmission and elicit an adaptive immune response. However, the function of other ISGs, besides CH25H, which play a critical role in innate immunity against herpes simplex virus type I, is unclear. Therefore, there is a need to find ISGs that can simultaneously regulate the body's metabolism and immune response to control herpes simplex virus type I infections.

Under inflammatory conditions and immune stimulation, kynurenine hydroxylase (KMO) expression is upregulated in pro-inflammatory macrophages. Quinolinic acid (Quinolinic acid) is a natural product synthesized by KMO, and a quinoline structure skeleton is an important pharmacophore and has wide application in the field of malaria resistance. In addition to antimalarial activity, quinoline compounds have a variety of biological activities, such as antituberculosis, antitumoral, etc. However, the application of kynurenine hydroxylase or quinolinic acid, a metabolite of kynurenine hydroxylase, in inhibiting the type I herpes simplex virus has not been reported.

Disclosure of Invention

In view of the problems in the prior art, the anti-I type herpes simplex virus (HSV-1) medicine can inhibit the replication of HSV-1, so that the titer of the HSV-1 is reduced.

In order to achieve the purpose, the invention adopts the following technical scheme:

in a first aspect, an anti-type i herpes simplex virus medicament, comprising: any one of kynurenine hydroxylase gene (KMO gene), kynurenine hydroxylase (KMO protein) or Quinolinic acid (Quinolinic acid), which is a metabolite of the kynurenine hydroxylase, or a combination of at least two thereof.

Experiments prove that the KMO gene belongs to an interferon activating gene, the overexpression of the KMO protein can inhibit the replication of HSV-1, test cells (such as 293T cells (human cells), Vero cells (monkey cells) and Raw264.7 cells (mouse cells) and the like) which are transferred into a KMO gene sequence are infected with HSV-1, and the replication of viruses in the cells is inhibited through the protein level and the gene level; and researches show that the expression quantity of IFNB in cells treated by quinoline acid which is a metabolite of KMO is improved, viruses can be effectively inhibited, and EC of the IFNB can be effectively inhibited₅₀0.3mM, quinolinic acid formula C₇H₅NO₄The structural formula is shown as formula I;

therefore, according to the experimental results, the KMO gene, the KMO protein and quinolinic acid are presumed to inhibit the inhibition of HSV-1 by inducing the production of IFNB.

The KMO gene can be constructed on different expression vectors according to the specific administration mode by a person skilled in the art, and KMO protein can be synthesized by adopting different methods or quinolinic acid can be prepared into different dosage forms so as to realize the maximum curative effect of the anti-I herpes simplex virus medicament.

As a preferred embodiment of the present invention, the kynurenine hydroxylase has any one of the amino acid sequences shown in (I), (II) or (III):

(I) an amino acid sequence as shown in SEQ ID NO.1 or 2;

(II) an amino acid sequence having homology of more than or equal to 85% with the amino acid sequence shown in SEQ ID NO.1 or 2;

(III) an amino acid sequence obtained by modifying, substituting, deleting or adding at least one amino acid in the amino acid sequence shown in SEQ ID NO.1 or 2.

Wherein, the amino acid sequences of SEQ ID NO.1 and 2 are shown as follows, wherein SEQ ID NO.1 is human (Homo sapiens) and SEQ ID NO.2 is murine (Mus musculus).

MDSSVIQRKKVAVIGGGLVGSLQACFLAKRNFQIDVYEAREDTRVATFTRGRSINLALSHRGRQALKAVGLEDQIVSQGIPMRARMIHSLSGKKSAIPYGTKSQYILSVSRENLNKDLLTAAEKYPNVKMHFNHRLLKCNPEEGMITVLGSDKVPKDVTCDLIVGCDGAYSTVRSHLMKKPRFDYSQQYIPHGYMELTIPPKNGDYAMEPNYLHIWPRNTFMMIALPNMNKSFTCTLFMPFEEFEKLLTSNDVVDFFQKYFPDAIPLIGEKLLVQDFFLLPAQPMISVKCSSFHFKSHCVLLGDAAHAIVPFFGQGMNAGFEDCLVFDELMDKFSNDLSLCLPVFSRLRIPDDHAISDLSMYNYIEMRAHVNSSWFIFQKNMERFLHAIMPSTFIPLYTMVTFSRIRYHEAVQRWHWQKKVINKGLFFLGSLIAISSTYLLIHYMSPRSFLRLRRPWNWIAHFRNTTCFPAKAVDSLEQISNLISR(SEQ ID NO.1)

MASSDTQGKRVAVIGGGLVGALNACFLAKRNFQVDVYEAREDIRVAKSARGRSINLALSYRGRQALKAIGLEDQIVSKGVPMKARMIHSLSGKKSAIPYGNKSQYILSISRENLNKDLLTAVESYANAKVHFGHKLSKCIPEEGVLTVLGPDKVPRDVTCDLVVGCDGAYSTVRAHLMKKPRFDYTQQYIPHGYMELTIPPKNGEYAMEPNCLHIWPRNAYMMIALPNMDKSFTCTLFMPFEEFERLPTRSDVLDFFQKNFPDAIPLMGEQALMRDFFLLPAQPMISVKCSPFHLKSHCVLMGDAAHAIVPFFGQGMNAGFEDCLVFDELMDKFNNNLSMCLPEFSRFRIPDDHAISDLSMYNYIEMRAHVNSRWFLFQKLLDKFLHAIMPSTFIPLYTMVAFTRIRYHEAVLRWHWQKKVINRGLFVLGSLIAIGGTYLLVHHLSLRPLEFLRRPAWMGTTGYWTRSTDISLQVPWSY(SEQ ID NO.2)

In a preferred embodiment of the present invention, the kynurenine hydroxylase gene has any one of the nucleotide sequences shown in (i), (ii) or (iii):

(i) a nucleotide sequence encoding kynurenine hydroxylase described in claim 2;

(ii) a nucleotide sequence encoding kynurenine hydroxylase shown in SEQ ID No.1 or 2;

(iii) the nucleotide sequence shown as SEQ ID NO.3 or 4.

Preferably, the amino acid sequence of the kynurenine hydroxylase is shown as SEQ ID No.1 or 2, and the nucleotide sequence of the kynurenine hydroxylase gene is shown as SEQ ID No.3 or 4.

As a preferable technical scheme, the anti-I type herpes simplex virus medicament also comprises pharmaceutically acceptable auxiliary materials.

Preferably, the pharmaceutically acceptable auxiliary materials include any one or a combination of at least two of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, bacteriostats or buffers.

As a preferred technical scheme, the administration route of the anti-type I herpes simplex virus medicament comprises the following steps: any one or the combination of at least two of intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.

In a second aspect, a process for the preparation of a medicament against herpes simplex virus type i according to the first aspect, comprising the steps of:

constructing a gene expression vector for expressing kynurenine hydroxylase, transferring the gene expression vector into an engineering strain and/or a cell, and mixing the engineering strain and/or the cell with a pharmaceutically acceptable auxiliary material to prepare the anti-I type herpes simplex virus medicament;

or constructing a gene expression vector for expressing the kynurenine hydroxylase, transferring the gene expression vector into an engineering strain and/or a cell to synthesize the kynurenine hydroxylase so as to obtain the kynurenine hydroxylase and/or quinolinic acid, and mixing the kynurenine hydroxylase and/or quinolinic acid with pharmaceutically acceptable auxiliary materials to prepare the anti-type I herpes simplex virus medicament.

Preferably, the gene expression vector contains at least one copy of a kynurenine hydroxylase gene;

preferably, the engineered strain comprises proeukaryotic and/or prokaryotic cells.

Preferably, the eukaryotic cell includes any one or a combination of two or more of a yeast cell, a mammalian cell, an insect cell, or a plant cell.

Preferably, the prokaryote comprises escherichia coli.

In a third aspect, the use of an anti-herpes simplex virus type i medicament as described in the first aspect for studying the pathogenesis of herpes simplex virus type i.

Meanwhile, the invention also relates to application of at least one of KMO gene, KMO protein and quinolinic acid in preventing and/or treating HSV-1 infection, in particular to application in inhibiting HSV-1 in vitro. Also, the present invention relates to a method of preventing and/or treating HSV-1 infection comprising administering an effective amount of quinolinic acid to a subject cell.

In a fourth aspect, the present invention also provides an interferon inducer comprising: any one or combination of at least two of kynurenine hydroxylase genes, kynurenine hydroxylase enzymes or a metabolite quinolinic acid of the kynurenine hydroxylase enzymes.

Preferably, the interferon inducer is targeted to type I interferon

It is noted that, in the present invention, without being stated to the contrary, terms such as "inhibiting HSV-1" are used to generally refer to inhibiting the replication of HSV-1, thereby reducing the titer of HSV-1; the HSV-1 is an HSV-1F strain commonly used in the field, is a DNA double-stranded virus with an envelope, and can cause cell infection and lesion through homologous recombination of viruses with a green fluorescent marker (GFP) and a firefly luciferase (Luc) marker; the test cells may be mammalian cells which are normally susceptible to HSV-1 infection, particularly primate cells (e.g. human 293T cells or monkey Vero cells) or rodent cells (e.g. murine Raw264.7 cells).

The recitation of numerical ranges herein includes not only the above-recited values, but also any values between any of the above-recited numerical ranges not recited, and for brevity and clarity, is not intended to be exhaustive of the specific values encompassed within the range.

Compared with the prior art, the invention has at least the following beneficial effects:

(1) the invention provides an anti-I type herpes simplex virus medicament, which comprises a KMO gene, KMO protein or a metabolite quinolinic acid thereof, and experiments prove that after the KMO gene is over-expressed to generate the KMO protein, the medicament can effectively inhibit the growth and reproduction of HSV-1, promote the expression of IFNB, and play a role in protecting a host, and meanwhile, if main sites of the KMO gene are mutated, the activity of the KMO gene is reduced, and the antiviral effect of the KMO gene is greatly influenced, so that the amino acid sequences shown in SEQ ID No.1 and 2 have better inhibition effect on HSV-1;

(2) the invention provides an anti-I type herpes simplex virus medicament which has low cytotoxicity, takes quinolinic acid as an example, does not show obvious cytotoxicity when the concentration is less than 2mM, and the EC of the quinolinic acid₅₀The content of the active component is 0.3mM, so that the anti-I herpes simplex virus medicine provided by the invention has better treatment effect and better biological safety.

Drawings

FIG. 1 is a bar graph showing the expression level of KMO gene after stimulation of Raw264.7 cells and IFN receptor-deficient cells using different TLRs, wherein A is a Raw264.7 cell and B is an IFN receptor-deficient cell.

FIG. 2 is a bar graph showing the expression levels of KMO mRNA and HSV-1 virus in cells after overexpression of GFP, KMO and CH25H, respectively, wherein A is the expression level of KMO mRNA, and B is the expression level of HSV-1 virus.

FIG. 3 is a Western blot of the amount of KMO and ICP27 protein expression in different experimental groups.

FIG. 4 is a graph of titer of HSV-1 in supernatants from viral plaque assays.

Figure 5 is a graph of titer of a monolayer of Vero cells at 95% confluence.

FIG. 6 is a histogram of KMO and HSV-1 virus expression levels after siRNA transfection, wherein, A is KMO expression level, and B is HSV-1 virus expression level.

FIG. 7 is a bar graph of KMO and HSV-1 virus expression levels after shRNA transfection, wherein, A is KMO expression level, and B is HSV-1 virus expression level.

Fig. 8 is a western blot assay following KMO knock-out using CRISPR/Cas9 system.

FIG. 9 is a histogram of HSV-1 virus expression levels obtained after overexpression of GFP, KMO and KMO-M, respectively, wherein panel A is analyzed by luciferase and panel B is analyzed by RT-qPCR.

FIG. 10 is a histogram of HSV-1 virus expression following overexpression of GFP, KMO and CH25H in KMO-deficient monoclonal cells, respectively.

FIG. 11(a) is a histogram of HSV-1 virus expression in Vero cells obtained by RT-qPCR detection.

FIG. 11(b) is a Western blot assay of the ICP27 protein expression levels of HSV-1 in 293T cells.

Figure 12(a) is a bar graph of cell viability after incubation of Vero cells with different concentrations of quinolinic acid.

FIG. 12(b) is a graph of the inhibitory effect on HSV-1 after incubation of Vero cells with quinolinic acid at various concentrations.

FIG. 12(c) is a histogram of HSV-1 virus expression levels after quinolinic acid treatment of Vero cells for various periods of time.

FIG. 13 is a histogram of the IFNB expression levels detected by RT-qPCR after transfection in different experimental groups; wherein A is A picture of different plasmid transfection, B picture is siRNA transfection, and C picture is shRNA transfection.

FIG. 14 is a histogram of IFNB expression after different concentrations of KMO inhibitor and quinolinic acid treatment of RAW264.7 cells, wherein panel A is KMO inhibitor treatment and panel B is quinolinic acid treatment.

Detailed Description

The technical solutions of the present invention are further described in the following embodiments with reference to the drawings, but the following examples are only simple examples of the present invention and do not represent or limit the scope of the present invention, which is defined by the claims.

In the following examples, room temperature means 20 ℃; in the following examples, HSV-1 refers to HSV-1F strains marked with GFP and Luc, and the experimental methods used in the examples are conventional methods unless otherwise specified.

Among them, LPS (Invitrogen, cat # 00-4976-93); poly (I: C) (Sigma, cat # P1530); r848(Stemcell, cat # 73784); reverse transcription kit

Plus II DNA (Whole gold, cat # BM121-02), qPCR kit 2 × SYBR Green PCR Mix (Whole gold, cat # AQ 601); KMO antibody (abcam, cat # ab 130959); ICP27 antibody (abcam, cat No. ab 53480); GAPDH antibody (abcam, cat ab 181602); ECL luminescence (fred bio, cat # FD 8020); 5 × two-color protein Loading buffer (friedren, cat # FD 002); 0.22 μm PVDF membrane (Michibo, cat # ISEQ 00010); protein maker (10-250kDa) (ThermoFisher, cat # 26619); phosphatase inhibitors (gold full, cat # DI 201-01); protease inhibitors (all formula gold, cat # DI 101-02); protein lysate RIPA (bi yun day, cat No. P0013B); PMSF (bi yun day, cat # ST 506); western primary anti-diluent (Biyuntian, cat # P0023A); 30% acrylamide (29:1) (Fred, cat # FD 2060); tris (powder) Tris (hydroxymethyl) aminomethane (friedel organisms, cat # FD 2010); ammonium persulfate (powder) APS (friedel bio, cat No. FD 2050); TEMED (fred, cat # FD 2100); BCA protein quantification kit (ThermoFisher, Cat. No. 23225); TBS powder (Dingguo, goods number BF-0153); tween-20 (fred bio, cat # FD 0020); triton (Biofrox, cat # 1)139ML 100); sodium bicarbonate (friedel organisms, cat # FD 5112); 4% paraformaldehyde fixing solution (Biyuntian, cargo number P0099-500 ml); crystal violet stain (seveibio, cat # G1014); low melting agarose (Promega, cat # V2111); TROIZOL (Invitrogen, cat # 15596026); transfection reagent Lipofectamine 2000(Invitrogen, cat # 12566014); lipofectamine RNA iMax (Invitrogen, cat # 13778500); polybrene (assist saint, cat # 40804ES 86); single point mutation kit (gold full, cat # FM 111-02); X-Gal galactoside (Biyuntian, cat # ST 912); IPTG isopropyl- β -D-thiogalactoside (bi yun, cat # ST 098); ampicillin (gold of full formula, cat # GG 101-01); kanamycin (holo-gold, cat # GG 201-01); luciferase assay kit (ladder-glociferase assay system) (Promega, cat # E2520); living cell assay CCK-8 kit (assist in san Francisco, cat # 40203ES 76); quinolinic acid QUIN (selelck, cat # S3624); KMO inhibitor Ro 61-8048(MCE, cat # HY-12347); unless otherwise specified, other materials, reagents, etc., which are not mentioned, are commercially available.

Example 1

This example verifies from the gene level that KMO belongs to an interferon-activated gene and has the effect of suppressing HSV-1.

To verify that KMO belongs to ISGs, different Toll-like receptor (TLRs) agonists were used in this example: LPS (1. mu.g/mL), R848(100nM) and polyI: C (25. mu.g/mL), stimulated two cells of Raw264.7 and IFN receptor-deficient (IFNR-/-) J2 BMMs for 4 hours, and cell lysates were taken for RT-qPCR to detect the expression level of KMO gene.

The method for RNA separation, reverse transcription and RT-qPCR detection comprises the following steps:

(1) RNA isolation: adding 1mL of TROIZOL reagent into cells, standing at room temperature for 5min, transferring into a 1.5mL centrifuge tube, adding 0.2mL of chloroform into the centrifuge tube, covering the centrifuge tube, holding the centrifuge tube by hand, swinging up and down for uniformly mixing for 15s, standing at room temperature for 2min, and centrifuging at 4 ℃ and 12000g for 15 min;

taking 0.5mL of centrifuged supernatant into a new centrifuge tube of 1.5mL, adding 0.5mL of absolute ethyl alcohol, turning upside down and mixing uniformly, and standing at room temperature for 10 min; centrifuging at 4 deg.C and 12000g for 10 min; after discarding the supernatant, adding 1mL of 75% ethanol into the centrifuge tube, tightly covering the centrifuge tube cover, and quickly vortexing;

centrifuging at 7500g at 4 deg.C for 5 min; discarding the supernatant after centrifugation, and drying at room temperature for 5 min; adding 20-50 μ L DEPC treated water for dissolving, and storing in ultra-low temperature refrigerator;

(2) reverse transcription and real-time quantitative PCR: using reverse transcription kits

And detecting the expression quantity of RNA by using Plus II DNA and a qPCR kit 2 multiplied by SYBR Green PCR Mix through an RT-qPCR technology. Primers used for RT-qPCR were designed using Primer 5 and synthesized in sangon with sequences shown in Table 1.

TABLE 1

SEQ ID NO.	Gene	Sequence(5′-3′)
			5	HSV-1-ΜL-27-F	GCCTTCTTCGCCTTTCGC
6	HSV-1ΜL-27-R	CGCTGTGCCCTTCTTCTT
			7	Homo-β-actin-F	CATGTACGTTGCTATCCAGGC
8	Homo-β-actin-R	CTCCTTAATGTCACGCACGAT
			9	Homo-KMO-F	ATGGACTCATCTGTCATTCAAAG
10	Homo-KMO-F	TGATCTTCCAGGCCAACAGCTTT
			11	Homo-IFNB-F	GCTTGGATTCCTACAAAGAAG
12	Homo-IFNB-R	ATAGATGGTCAATGCGGCGTC
			13	Mus-β-actin-F	CGTTGACATCCGTAAAGACC
14	Mus-β-actin-R	TAGGAGCCAGAGCAGTAATC
			15	Mus-KMO-F	ATGGCATCGTCTGATACTCAGG
16	Mus-KMO-F	CTTCTTTCCCGAAAGAGAGTGG
			17	Mus-IFNB-F	TCACCTACAGGGCGGACTTC
18	Mus-IFNB-R	TCTCTGCTCGGACCACCATC

The 20 μ L reaction system used was as follows (amount per well):

2 × reaction buffer, 10 μ L; 10 μ M forward primer, 0.5 μ L; 10 μ M reverse primer, 0.5 μ L; template cDNA, 2. mu.L; h₂O，7μL。

The reaction procedure was as follows:

95.0 deg.C for 3 min; circulating for 44 times at 95.0 deg.C for 10sec, 56.0 deg.C for 30 sec; the melting curve is 65-95 ℃, and the temperature for each increase is 0.5 ℃;

the program was executed using CFX Connect read Time Detection System (Bio-Rad Laboratories) while using beta-actin as a reference gene and 2^-ΔΔCtThe method calculates the relative expression level of the gene.

The results are shown in FIG. 1, in which A is Raw264.7 cells and B is IFN receptor deficient (IFNR-/-) J2 BMMs cells. As can be seen by comparing FIG. 1, KMO expression was reduced or unaffected in cells of IFNR-/-J2 BMMs when treated with the same agonist, indicating that KMO expression was dependent on IFN. Thus, KMO belongs to the interferon-activated gene.

It is further evaluated in this example whether overexpression of KMO can inhibit the growth of HSV-1.

293T cells were transfected with plasmids (1. mu.g) overexpressing GFP (pVAX-GFP, negative control), KMO (pVAX-KMO), CH25H (pVAX-CH25H, positive control) for 24 hours, and then infected with HSV-1(0.25MOI) for 8 hours, and KMO mRNA and HSV-1 virus expression were detected by RT-qPCR, respectively.

The results are shown in FIG. 2, wherein A represents the expression level of KMO mRNA, and B represents the expression level of HSV-1 virus; as can be seen, overexpression of KMO in 293T cells significantly inhibited HSV-1 replication, similar to the inhibition by CH 25H.

Example 2

This example demonstrates from protein as well as cellular levels that overexpression of KMO has inhibitory effects on HSV-1 infection. The specific method comprises the following steps:

(1) western blotting (Western blotting)

Preparing a lysate (RIPA: PMSF: protease inhibitor: phosphatase inhibitor ═ 100:1:1: 1); removing culture solution from cells in 6-well plate, placing on ice, adding 200 μ L lysate per well, placing in 4 deg.C refrigerator shaking table, and fully lysing for 20 min; scraping cells by using a cell scraper, and transferring the cells into a centrifuge tube; centrifuging at 12000g and 4 ℃ for 15min, and sucking 160 mu L of supernatant into a new centrifuge tube; adding 40 μ L of 5 × protein loading buffer;

heating and denaturing at 100 deg.c for 10 min; the remaining supernatant was used for BCA measurement of protein concentration; adjusting the protein concentration of each sample to be consistent, and storing the protein after heating denaturation at-20 ℃;

preparing 10% SDS-PAGE gel, carrying out electrophoresis at the voltage of 120V after the sample runs out of the concentrated gel and the voltage of 60V is 1 h; cutting a PVDF membrane with a proper size, and soaking in methanol for 10 min; taking down the SDS-PAGE gel, sequentially putting down a layer of sponge, a layer of filter paper, a PVDF membrane, gel, a layer of filter paper and a layer of sponge according to the sequence from the anode to the cathode, and putting the layers of sponge in a membrane transfer buffer solution; after the membrane is rotated for 3 hours at 250mA, the membrane is immersed in 5 percent of skimmed milk, and the membrane is sealed for 1 hour after 60 revolutions;

hybridizing the antibody diluted by 1:2000 at 4 ℃ in a shaking table overnight; after the primary antibody is recovered, washing the membrane for 3 times with TBST, 10min each time; adding a secondary antibody diluted by TBST, and incubating for 1h after 60-turn incubation; washing the membrane for 3 times by TBST, 10min each time; chemiluminescence: and mixing the luminescent solution A and the luminescent solution B in a ratio of 1:1, dripping the mixture on the front surface of the PVDF membrane in a dark place for development, and performing gray scale analysis by using imageJ software.

Detecting the ICP27 protein expression quantity of KMO and HSV-1 by a western blotting method, wherein the ratio of KMO to GAPDH is 1.0, 2.2 and 1.4 respectively; the ratios of ICP27 to GAPDH were 1.0, 0.5, and 0.6, respectively. As shown in FIG. 3, the protein expression level of KMO in pVAX-KMO is higher, indicating that the protein level of HSV-1 can be effectively inhibited.

(2) Plaque detection

Infectious virus can be quantified by a viral plaque formation assay to evaluate the effect of KMO overexpression on HSV-1.

Vero cells were cultured in 6-well plates (4 plates) at a concentration of 70% (fusion cells 1:3 dilution) to reach 90% confluence the next day;

1.6mL of 1 × DMEM was added to each tube and named, and 16 μ L of virus stock was added to the first tube using a pipette and Vertex for a sufficient time; will 10^-2(16. mu.L) was transferred to the next tube to obtain 10^-4Diluting, and mixing 16 μ L10^-4Dilution was transferred to the next tube to obtain 10^-6Dilution and repetition until 10 is reached^-8Dilution, labeling each well with dilution order (3 replicates three per dilution); the medium was discarded and 0.5mL of the dilution was added to each of the 6 wells at 37 ℃ with 5% CO₂Incubating for 2h to ensure virus absorption, and inclining the inoculum every 30 minutes to ensure uniform infection and no stem cells; in this experiment, 10 was used^-5，10^-6，10^-7And 10^-8Dilution and infection simulation;

during incubation in ddH₂High pressure sterilizing 2X 2% low melting point agarose in O, placing in a 42 ℃ incubator to prevent coagulation, preparing 27mL of 2X DMEM and incubating at 37 ℃, mixing agarose and DMEM of the previous step in a ratio of 1: 1; discard viral inoculum and add 2mL of mixture quickly to each well to avoid clotting, incubate until plaques are visible;

add 2mL of 4% formaldehyde to 6 wells per well, incubate for 1 hour, rinse with tap water to remove the gel medium and fix the solution; PFA was discarded and 1mL of diluted crystal violet stain was added to each well, incubation continued for 60 minutes, stain removed and cells rinsed with cold tap water until the liquid was clear, 6 well plates were placed upside down on a paper towel, plaques magnified 10 times and counted,

the number of plaques is shown in figure 4 and titers are titrated in a monolayer of Vero cells at 95% fusion, as shown in figure 5, KMO significantly inhibited virus growth.

Example 3

In the embodiment, the influence of KMO on HSV-1 is studied by down-regulating the expression amount of KMO.

To investigate the effect of KMO down-regulation and mutation on HSV-1 replication, small interfering RNA (siRNA) was used in this example to silence the expression of KMO in 293T cells. The specific method comprises the following steps:

(1) SiRNA silencing

Synthetic sirna (genepharma) was transfected into 293T cells using Lipofectamine RNA iMax. RNA samples were harvested 48 hours after transfection for RT-qPCR detection. The sequences of all siRNAs are listed in Table 2 and all RT-qPCR primers are listed in Table 1.

Transfecting 293T cells with siRNA lentivirus for 24 hours, then infecting the cells with HSV-1(0.25MOI) for 8 hours, and respectively detecting KMO expression and HSV-1 virus expression by RT-qPCR to obtain a graph shown in figure 6, wherein A is KMO expression amount, and B is HSV-1 virus expression amount. Expression of KMO was significantly reduced after siKMO treatment, and downregulation of KMO was observed to increase the level of viral replication.

(2) Construction of shRNA Virus

shRNA-KMO was designed using the siRNA design tool on http:// siRNA. wi. mit. edu/, and the three highest scoring targets were selected. Based on the target gene, forward and reverse oligonucleotides were synthesized, annealed, and then cloned into plko.1 vector. Plasmid psPAX2, enveloped plasmid pmd2.g, was packaged by co-transfection of 293T cells with a plko.1shrna plasmid cocktail using transfection reagents to generate shRNA virus, the primers used are listed in table 2.

And transfecting 293T cells for 24 hours by using shRNA lentivirus, infecting the cells for 8 hours by using HSV-1(0.25MOI), and respectively detecting KMO expression and HSV-1 virus expression by RT-qPCR (reverse transcription-quantitative polymerase chain reaction), thereby obtaining a graph 7, wherein A is KMO expression quantity, and B is HSV-1 virus expression quantity. The expression of small interfering RNA in 293T cells using the shKMO lentiviral vector also showed the same results as siRNA.

(3) Knock-out of KMO and construction of KMO-/-293T cells

To further determine the role of KMO in HSV-1 infection, KMO knockout 293T cells were generated using the CRISPR/Cas9 system.

Single guide RNA (sgRNA) was designed using CRISPR design tool (http:// zlab. bio/guide-design-resources): sgRNA-KMO, and the three highest scoring oligonucleotides were selected and ligated into pLentiCRISPRV2(Addgene #52961), respectively. Plasmids pmd2.g (addge #12259) and psPAX2(addge #12260) were packaged by co-transfecting a lentiviral vector with a lentiviral CRISPRv2 mixture using transfection reagents to generate sgrnas, the primers used being listed in table 2.

Pseudovirions sgKMO mixed Polybrene infected 293T cells of interest, followed by selection of stable cell lines with puromycin. Cells were selected using limiting dilutions and analyzed by western blot and DNA sequencing; luciferase activity was then detected using a luciferase assay kit assay system.

KMO DNA changes and protein expression were detected in sgNC 293T and sgKMO monoclonal 293T cells (KMO-/-293T monoclonal cell line selected by limiting dilution) by Western blotting, and the results are shown in FIG. 8, demonstrating KMO knock-out by Western blotting.

(4) Construction of KMO mutant vector KMO-M

The activity of the KMO enzyme is crucial to the function of KMO, so the enzyme active site of KMO is mutated in this example. Single point mutagenesis kit A KMO hydroxylase activity mutant (KMO-M) was mutated from a pVAX-KMO construct, the primers used are listed in Table 2, and all sequences were synthesized in sangon.

293T cells were transfected with 1. mu.g each of plasmids expressing GFP, KMO and KMO-M for 24 hours, and then infected with HSV-1(0.25MOI) for 8 hours, and the HSV-1 virus expression levels were determined by luciferase assay and RT-qPCR, respectively.

In FIG. 9, A is the result of luciferase assay, B is the result of RT-qPCR assay, and the detection results show that overexpression of KMO can inhibit HSV-1, and KMO-deficient cells are susceptible to HSV-1 infection. In conclusion, KMO has the function of inhibiting HSV-1 replication. As shown in FIG. 9, overexpression of KMO-M (with mutations in the active site of the enzyme) had no significant effect on HSV-1 infection.

Thus, it was the KMO-transfected sample that inhibited viral replication but not KMO-M, indicating that KMO enzymatic activity is critical to its antiviral function.

TABLE 2

(6) Anaplerotic experiment

KMO was transfected into KMO-/-293T monoclonal cell line and it was observed whether the virus could be inhibited by the expression of KMO in a complementation.

KMO-/-monoclonal cells were transfected with 1. mu.g each of plasmids overexpressing GFP, KMO, CH25H for 24 hours, and then infected with HSV-1(0.25MOI) for 8 hours, and HSV-1 virus expression was detected by RT-qPCR. The results are shown in FIG. 10, in which the virus production was reduced in the KMO and CH25H groups compared to the GFP group.

Example 4

This example is used to verify that the metabolite quinolinic acid has an anti-HSV-1 effect.

To investigate whether KMO can produce soluble anti-HSV-1 factor. Transfecting 293T cells with a plasmid expressing KMO, CH25H, GFP, and after 24 hours, pretreating Vero cells and 293T cells for 24 hours respectively, and then infecting the pretreated cells with HSV-1(0.25MOI) for 24 hours;

the expression level of HSV-1 virus in Vero cells is detected by RT-qPCR to obtain a graph 11(a), and the expression level of ICP27 protein of HSV-1 in 293T cells is detected by a western blotting method to obtain a graph 11(b), wherein the ratio of ICP27 to GAPDH is 1.0, 0.7 and 0.5 respectively. As can be seen, the supernatant of 293T cells overexpressing KMO, CH25H significantly inhibited HSV-1 infection in Vero cells and 293T cells. Western blot analysis also showed the same results.

The above results demonstrate that KMO produces soluble anti-HSV-1 factor. KMO is a key enzyme in the kynurenine pathway, the activity of which promotes the production of quinolinic acid.

Meanwhile, in the embodiment, CCK8 is used for detecting and researching the cytotoxicity of quinolinic acid, and the method comprises the following specific steps:

vero cells (1X 10)⁴) Inoculating into 96-well plate, adding quinolinic acid, incubating for 72 hr, taking out 96-well plate and dissolving 10 μ L CCK8The solution was added to each well and incubated at 37 ℃ for 1 hour in the dark. The OD value at 450nm was measured with a microplate reader.

Vero cells were pre-treated with quinolinic acid at the indicated concentration for 72 hours, then tested for CCK8 to determine quinolinic acid cytotoxicity, and DMSO-treated samples were set for cell viability to 1. As shown in FIG. 12(a), quinolinic acid did not show significant cytotoxicity at concentrations less than 2 mM.

In the embodiment, CCK8 is also used for detecting the influence of HSV-1 on the cell viability after the pretreatment of quinolinic acid, and the specific steps are as follows:

vero cells (1X 10)⁴) Plating into 96-well plates. Pre-treated with quinolinic acid at the indicated concentration for 8 hours, and then the cells were infected with HSV-1(0.1MOI) for 48 hours. The plates were removed and 10 μ L of CCK8 solution was added to each well and incubated at 37 ℃ for 1 hour in the dark. OD at 450nm was measured with a microplate reader to determine the viability of the cells after infection. As shown in FIG. 12(b), EC of quinolinic acid₅₀＝0.3mM。

Vero cells were pretreated with quinolinic acid (1mM) at different hours, then infected with HSV-1(0.25MOI) for 8 hours, and HSV-1 virus expression was detected by RT-qPCR, as shown in FIG. 12(c), which had better inhibitory effect on HSV-1 for 8 hours.

Example 5

This example was used to study the mechanism of KMO-mediated inhibition of HSV-1, and the effect of KMO overexpression on cytokines.

(1) Transfecting RAW264.7 cells with 1 mu g of plasmids of over-expressing GFP and KMO and siRNA or shRNA lentivirus for 24 hours respectively, then infecting the cells for 8 hours by HSV-1(0.25MOI), and detecting IFNB expression by RT-qPCR; the results are shown in FIG. 13, where A is the transfection of different plasmids, B is the siRNA transfection, and C is the shRNA transfection.

The results indicate that overexpression of KMO promotes IFNB expression, which is a result of effective inhibition of HSV-1 replication, while KMO deficiency reduces IFNB expression, resulting in susceptibility to HSV-1 infection.

(2) RAW264.7 cells were pretreated with a KMO inhibitor at the indicated concentration for 24 hours, then infected with HSV-1(0.25MOI) for 8 hours, and the expression level of IFNB was determined by RT-qPCR.

(3) RAW264.7 cells were pre-treated with quinolinic acid at various concentrations for 24 hours, and then infected with HSV-1(0.25MOI) for 8 hours. The expression level of IFNB was determined by RT-qPCR.

As shown in FIG. 14, A shows that the expression of IFNB is reduced in a dose-dependent manner when the inhibitor is used to inhibit KMO enzymatic activity; the graph B shows that quinolinic acid also effectively promotes the expression of IFNB, and the higher the concentration of quinolinic acid, the more the expression of IFNB is stimulated. Thus, KMO and quinolinic acid inhibit HSV-1 by inducing the production of IFNB.

In conclusion, the kynurenine hydroxylase gene belongs to an interferon activating gene, and after the kynurenine hydroxylase gene is overexpressed to generate the kynurenine hydroxylase, the expression of IFNB in host cells can be promoted, the growth and the propagation of HSV-1 can be effectively inhibited, and the host cells can be protected.

The applicant declares that the above description is only a specific embodiment of the present invention, but the scope of the present invention is not limited thereto, and it should be understood by those skilled in the art that any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are within the scope and disclosure of the present invention.

Sequence listing

<110> Zhongshan university

<120> anti-I type herpes simplex virus medicine, preparation method and application thereof

<130> 20200909

<160> 28

<170> SIPOSequenceListing 1.0

<210> 1

<211> 486

<212> PRT

<213> Homo sapiens

<400> 1

Met Asp Ser Ser Val Ile Gln Arg Lys Lys Val Ala Val Ile Gly Gly

1 5 10 15

Gly Leu Val Gly Ser Leu Gln Ala Cys Phe Leu Ala Lys Arg Asn Phe

20 25 30

Gln Ile Asp Val Tyr Glu Ala Arg Glu Asp Thr Arg Val Ala Thr Phe

35 40 45

Thr Arg Gly Arg Ser Ile Asn Leu Ala Leu Ser His Arg Gly Arg Gln

50 55 60

Ala Leu Lys Ala Val Gly Leu Glu Asp Gln Ile Val Ser Gln Gly Ile

65 70 75 80

Pro Met Arg Ala Arg Met Ile His Ser Leu Ser Gly Lys Lys Ser Ala

85 90 95

Ile Pro Tyr Gly Thr Lys Ser Gln Tyr Ile Leu Ser Val Ser Arg Glu

100 105 110

Asn Leu Asn Lys Asp Leu Leu Thr Ala Ala Glu Lys Tyr Pro Asn Val

115 120 125

Lys Met His Phe Asn His Arg Leu Leu Lys Cys Asn Pro Glu Glu Gly

130 135 140

Met Ile Thr Val Leu Gly Ser Asp Lys Val Pro Lys Asp Val Thr Cys

145 150 155 160

Asp Leu Ile Val Gly Cys Asp Gly Ala Tyr Ser Thr Val Arg Ser His

165 170 175

Leu Met Lys Lys Pro Arg Phe Asp Tyr Ser Gln Gln Tyr Ile Pro His

180 185 190

Gly Tyr Met Glu Leu Thr Ile Pro Pro Lys Asn Gly Asp Tyr Ala Met

195 200 205

Glu Pro Asn Tyr Leu His Ile Trp Pro Arg Asn Thr Phe Met Met Ile

210 215 220

Ala Leu Pro Asn Met Asn Lys Ser Phe Thr Cys Thr Leu Phe Met Pro

225 230 235 240

Phe Glu Glu Phe Glu Lys Leu Leu Thr Ser Asn Asp Val Val Asp Phe

245 250 255

Phe Gln Lys Tyr Phe Pro Asp Ala Ile Pro Leu Ile Gly Glu Lys Leu

260 265 270

Leu Val Gln Asp Phe Phe Leu Leu Pro Ala Gln Pro Met Ile Ser Val

275 280 285

Lys Cys Ser Ser Phe His Phe Lys Ser His Cys Val Leu Leu Gly Asp

290 295 300

Ala Ala His Ala Ile Val Pro Phe Phe Gly Gln Gly Met Asn Ala Gly

305 310 315 320

Phe Glu Asp Cys Leu Val Phe Asp Glu Leu Met Asp Lys Phe Ser Asn

325 330 335

Asp Leu Ser Leu Cys Leu Pro Val Phe Ser Arg Leu Arg Ile Pro Asp

340 345 350

Asp His Ala Ile Ser Asp Leu Ser Met Tyr Asn Tyr Ile Glu Met Arg

355 360 365

Ala His Val Asn Ser Ser Trp Phe Ile Phe Gln Lys Asn Met Glu Arg

370 375 380

Phe Leu His Ala Ile Met Pro Ser Thr Phe Ile Pro Leu Tyr Thr Met

385 390 395 400

Val Thr Phe Ser Arg Ile Arg Tyr His Glu Ala Val Gln Arg Trp His

405 410 415

Trp Gln Lys Lys Val Ile Asn Lys Gly Leu Phe Phe Leu Gly Ser Leu

420 425 430

Ile Ala Ile Ser Ser Thr Tyr Leu Leu Ile His Tyr Met Ser Pro Arg

435 440 445

Ser Phe Leu Arg Leu Arg Arg Pro Trp Asn Trp Ile Ala His Phe Arg

450 455 460

Asn Thr Thr Cys Phe Pro Ala Lys Ala Val Asp Ser Leu Glu Gln Ile

465 470 475 480

Ser Asn Leu Ile Ser Arg

485

<210> 2

<211> 479

<212> PRT

<213> Mus musculus

<400> 2

Met Ala Ser Ser Asp Thr Gln Gly Lys Arg Val Ala Val Ile Gly Gly

1 5 10 15

Gly Leu Val Gly Ala Leu Asn Ala Cys Phe Leu Ala Lys Arg Asn Phe

20 25 30

Gln Val Asp Val Tyr Glu Ala Arg Glu Asp Ile Arg Val Ala Lys Ser

35 40 45

Ala Arg Gly Arg Ser Ile Asn Leu Ala Leu Ser Tyr Arg Gly Arg Gln

50 55 60

Ala Leu Lys Ala Ile Gly Leu Glu Asp Gln Ile Val Ser Lys Gly Val

65 70 75 80

Pro Met Lys Ala Arg Met Ile His Ser Leu Ser Gly Lys Lys Ser Ala

85 90 95

Ile Pro Tyr Gly Asn Lys Ser Gln Tyr Ile Leu Ser Ile Ser Arg Glu

100 105 110

Asn Leu Asn Lys Asp Leu Leu Thr Ala Val Glu Ser Tyr Ala Asn Ala

115 120 125

Lys Val His Phe Gly His Lys Leu Ser Lys Cys Ile Pro Glu Glu Gly

130 135 140

Val Leu Thr Val Leu Gly Pro Asp Lys Val Pro Arg Asp Val Thr Cys

145 150 155 160

Asp Leu Val Val Gly Cys Asp Gly Ala Tyr Ser Thr Val Arg Ala His

165 170 175

Leu Met Lys Lys Pro Arg Phe Asp Tyr Thr Gln Gln Tyr Ile Pro His

180 185 190

Gly Tyr Met Glu Leu Thr Ile Pro Pro Lys Asn Gly Glu Tyr Ala Met

195 200 205

Glu Pro Asn Cys Leu His Ile Trp Pro Arg Asn Ala Tyr Met Met Ile

210 215 220

Ala Leu Pro Asn Met Asp Lys Ser Phe Thr Cys Thr Leu Phe Met Pro

225 230 235 240

Phe Glu Glu Phe Glu Arg Leu Pro Thr Arg Ser Asp Val Leu Asp Phe

245 250 255

Phe Gln Lys Asn Phe Pro Asp Ala Ile Pro Leu Met Gly Glu Gln Ala

260 265 270

Leu Met Arg Asp Phe Phe Leu Leu Pro Ala Gln Pro Met Ile Ser Val

275 280 285

Lys Cys Ser Pro Phe His Leu Lys Ser His Cys Val Leu Met Gly Asp

290 295 300

Ala Ala His Ala Ile Val Pro Phe Phe Gly Gln Gly Met Asn Ala Gly

305 310 315 320

Phe Glu Asp Cys Leu Val Phe Asp Glu Leu Met Asp Lys Phe Asn Asn

325 330 335

Asn Leu Ser Met Cys Leu Pro Glu Phe Ser Arg Phe Arg Ile Pro Asp

340 345 350

Asp His Ala Ile Ser Asp Leu Ser Met Tyr Asn Tyr Ile Glu Met Arg

355 360 365

Ala His Val Asn Ser Arg Trp Phe Leu Phe Gln Lys Leu Leu Asp Lys

370 375 380

Phe Leu His Ala Ile Met Pro Ser Thr Phe Ile Pro Leu Tyr Thr Met

385 390 395 400

Val Ala Phe Thr Arg Ile Arg Tyr His Glu Ala Val Leu Arg Trp His

405 410 415

Trp Gln Lys Lys Val Ile Asn Arg Gly Leu Phe Val Leu Gly Ser Leu

420 425 430

Ile Ala Ile Gly Gly Thr Tyr Leu Leu Val His His Leu Ser Leu Arg

435 440 445

Pro Leu Glu Phe Leu Arg Arg Pro Ala Trp Met Gly Thr Thr Gly Tyr

450 455 460

Trp Thr Arg Ser Thr Asp Ile Ser Leu Gln Val Pro Trp Ser Tyr

465 470 475

<210> 3

<211> 1461

<212> DNA

<213> Homo sapiens

<400> 3

atggactcat ctgtcattca aaggaaaaaa gtagctgtca ttggtggtgg cttggttggc 60

tcattacaag catgctttct tgcaaagagg aatttccaga ttgatgtata tgaagctagg 120

gaagatactc gagtggctac cttcacacgt ggaagaagca ttaacttagc cctttctcat 180

agaggacgac aagccttgaa agctgttggc ctggaagatc agattgtatc ccaaggtatt 240

cccatgagag caagaatgat ccactctctt tcaggaaaaa agtctgcaat tccctatggg 300

acaaagtctc agtatattct ttctgtaagc agagaaaatc taaacaagga tctattgact 360

gctgctgaga aataccccaa tgtgaaaatg cactttaacc acaggctgtt gaaatgtaat 420

ccagaggaag gaatgatcac agtgcttgga tctgacaaag ttcccaaaga tgtcacttgt 480

gacctcattg taggatgtga tggagcctat tcaactgtca gatctcacct gatgaagaaa 540

cctcgctttg attacagtca gcagtacatt cctcatgggt acatggagtt gactattcca 600

cctaagaacg gagattatgc catggaacct aattatctgc atatttggcc tagaaatacc 660

tttatgatga ttgcacttcc taacatgaac aaatcattca catgtacttt gttcatgccc 720

tttgaagagt ttgaaaaact tctaaccagt aatgatgtgg tagatttctt ccagaaatac 780

tttccggatg ccatccctct aattggagag aaactcctag tgcaagattt cttcctgttg 840

cctgcccagc ccatgatatc tgtaaagtgc tcttcatttc actttaaatc tcactgtgta 900

ctgctgggag atgcagctca tgctatagtg ccgttttttg ggcaaggaat gaatgcgggc 960

tttgaagact gcttggtatt tgatgagtta atggataaat tcagtaacga ccttagtttg 1020

tgtcttcctg tgttctcaag attgagaatc ccagatgatc acgcgatttc agacctatcc 1080

atgtacaatt acatagagat gcgagcacat gtcaactcaa gctggttcat ttttcagaag 1140

aacatggaga gatttcttca tgcgattatg ccatcgacct ttatccctct ctatacaatg 1200

gtcacttttt ccagaataag ataccatgag gctgtgcagc gttggcattg gcaaaaaaag 1260

gtgataaaca aaggactctt tttcttggga tcactgatag ccatcagcag tacctaccta 1320

cttatacact acatgtcacc acgatctttc ctccgcttga gaagaccatg gaactggata 1380

gctcacttcc ggaatacaac atgtttcccc gcaaaggccg tggactccct agaacaaatt 1440

tccaatctca ttagcaggtg a 1461

<210> 4

<211> 1440

<212> DNA

<213> Mus musculus

<400> 4

atggcatcgt ctgatactca ggggaaaaga gtggctgtta ttggcggtgg tttggttgga 60

gcactgaatg cctgctttct tgcaaagagg aattttcaag ttgatgtgta cgaagctagg 120

gaagatattc gcgtggctaa atctgcacgt ggaaggagca ttaacttggc cctttcttat 180

agaggacggc aggccttgaa agccattggt ctggaagatc agatcgtttc caaaggtgtg 240

cccatgaaag ccagaatgat ccactctctt tcgggaaaga agtctgcaat tccctatggg 300

aacaagtcac agtatatcct ttcaataagc agagaaaact taaacaagga cctgctgact 360

gccgtggagt cctatgccaa tgcgaaggtg cactttggcc acaagctgtc gaaatgcatt 420

ccggaggaag gggtactcac agtgctcgga cctgacaagg ttccccgaga tgtcacatgt 480

gaccttgttg tagggtgtga tggagcctat tcaactgtca gagcccacct catgaagaag 540

ccccgctttg attacactca gcaatatatc cctcatggat acatggagtt gacaattcca 600

cctaagaatg gggagtacgc catggaacct aactgtcttc acatttggcc tagaaatgcc 660

tatatgatga tcgcccttcc aaacatggac aaatctttca catgcacctt gttcatgccc 720

tttgaggagt ttgaaagact tccaacgcgc agcgatgtgc tggacttctt ccagaagaac 780

tttccagatg ctatccctct gatgggagag caagccctca tgagagattt ctttctgttg 840

cctgcccagc ccatgatatc agtgaagtgc tctcccttcc acctgaagtc acactgtgtg 900

ctgatgggag atgccgctca tgccattgtc ccattttttg ggcaaggaat gaatgcgggc 960

tttgaagact gcttggtgtt tgatgaattg atggacaaat tcaataataa tcttagtatg 1020

tgccttcctg aattctcaag atttaggatc ccagatgacc atgcaatttc agacctatct 1080

atgtacaatt acatagagat gcgagcgcat gtcaactcta ggtggttcct gttccaaaag 1140

ctcctggata aatttcttca cgcgatcatg ccctctacct ttatccctct ctataccatg 1200

gtcgccttca ccagaataag ataccacgag gcagtgctgc gttggcattg gcaaaaaaag 1260

gtgataaaca gaggactctt tgtccttggg tccctgatag ccattggagg cacctaccta 1320

cttgtgcacc atctgtccct gagacctctg gagttcttga gaagacctgc ctggatggga 1380

accactggct actggactag gagtacagac atttctctgc aagttccatg gagttactag 1440

<210> 5

<211> 18

<212> DNA

<213> Artificial Synthesis ()

<400> 5

gccttcttcg cctttcgc 18

<210> 6

<211> 18

<212> DNA

<213> Artificial Synthesis ()

<400> 6

cgctgtgccc ttcttctt 18

<210> 7

<211> 21

<212> DNA

<213> Artificial Synthesis ()

<400> 7

catgtacgtt gctatccagg c 21

<210> 8

<211> 21

<212> DNA

<213> Artificial Synthesis ()

<400> 8

ctccttaatg tcacgcacga t 21

<210> 9

<211> 23

<212> DNA

<213> Artificial Synthesis ()

<400> 9

atggactcat ctgtcattca aag 23

<210> 10

<211> 23

<212> DNA

<213> Artificial Synthesis ()

<400> 10

tgatcttcca ggccaacagc ttt 23

<210> 11

<211> 21

<212> DNA

<213> Artificial Synthesis ()

<400> 11

gcttggattc ctacaaagaa g 21

<210> 12

<211> 21

<212> DNA

<213> Artificial Synthesis ()

<400> 12

atagatggtc aatgcggcgt c 21

<210> 13

<211> 20

<212> DNA

<213> Artificial Synthesis ()

<400> 13

cgttgacatc cgtaaagacc 20

<210> 14

<211> 20

<212> DNA

<213> Artificial Synthesis ()

<400> 14

taggagccag agcagtaatc 20

<210> 15

<211> 22

<212> DNA

<213> Artificial Synthesis ()

<400> 15

atggcatcgt ctgatactca gg 22

<210> 16

<211> 22

<212> DNA

<213> Artificial Synthesis ()

<400> 16

cttctttccc gaaagagagt gg 22

<210> 17

<211> 20

<212> DNA

<213> Artificial Synthesis ()

<400> 17

tcacctacag ggcggacttc 20

<210> 18

<211> 20

<212> DNA

<213> Artificial Synthesis ()

<400> 18

tctctgctcg gaccaccatc 20

<210> 19

<211> 19

<212> DNA

<213> Artificial Synthesis ()

<400> 19

ggagcctatt caactgtca 19

<210> 20

<211> 25

<212> DNA

<213> Artificial Synthesis ()

<400> 20

caccgagcta gggaagatac tcgag 25

<210> 21

<211> 25

<212> DNA

<213> Artificial Synthesis ()

<400> 21

aaacctcgag tatcttccct agctc 25

<210> 22

<211> 58

<212> DNA

<213> Artificial Synthesis ()

<400> 22

ccggccacag gctgttgaaa tgtaactcga gttacatttc aacagcctgt ggtttttg 58

<210> 23

<211> 58

<212> DNA

<213> Artificial Synthesis ()

<400> 23

aattcaaaaa ccacaggctg ttgaaatgta actcgagtta catttcaaca gcctgtgg 58

<210> 24

<211> 21

<212> DNA

<213> Artificial Synthesis ()

<400> 24

ccuuccaaac auggacaaat t 21

<210> 25

<211> 25

<212> DNA

<213> Artificial Synthesis ()

<400> 25

caccgtccag cacatcgctg cgcgt 25

<210> 26

<211> 25

<212> DNA

<213> Artificial Synthesis ()

<400> 26

aaacacgcgc agcgatgtgc tggac 25

<210> 27

<211> 58

<212> DNA

<213> Artificial Synthesis ()

<400> 27

ccggctttga ttacactcag caatactcga gtattgctga gtgtaatcaa agtttttg 58

<210> 28

<211> 58

<212> DNA

<213> Artificial Synthesis ()

<400> 28

aattcaaaaa ctttgattac actcagcaat actcgagtat tgctgagtgt aatcaaag 58

Claims

1. An anti-type I herpes simplex virus medicament, which is characterized by comprising:

any one or combination of at least two of kynurenine hydroxylase genes, kynurenine hydroxylase enzymes or a metabolite quinolinic acid of the kynurenine hydroxylase enzymes.

2. The anti-type I herpes simplex virus drug of claim 1, wherein the kynurenine hydroxylase has any one of the amino acid sequences shown in (I), (II) or (III):

(I) an amino acid sequence as shown in SEQ ID NO.1 or 2;

3. The anti-type i herpes simplex virus drug of claim 1 or 2, wherein the kynurenine hydroxylase gene has any one of the nucleotide sequences shown in (i), (ii) or (iii):

(i) a nucleotide sequence encoding kynurenine hydroxylase described in claim 2;

(iii) the nucleotide sequence shown as SEQ ID NO.3 or 4.

4. The anti-type I herpes simplex virus drug of any one of claims 1 to 3, wherein the amino acid sequence of the kynurenine hydroxylase is shown as SEQ ID No.1 or 2, and the nucleotide sequence of the kynurenine hydroxylase gene is shown as SEQ ID No.3 or 4.

5. The anti-I herpes simplex virus medicament of any one of claims 1 to 4, further comprising a pharmaceutically acceptable excipient;

6. The anti-type i herpes simplex virus medicament of any one of claims 1 to 5, wherein the anti-type i herpes simplex virus medicament is administered by a route comprising: any one or the combination of at least two of intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.

7. A process for the preparation of a medicament according to any one of claims 1 to 6 against herpes simplex virus type I, comprising the steps of:

alternatively, the first and second electrodes may be,

constructing a gene expression vector for expressing kynurenine hydroxylase, transferring the gene expression vector into an engineering strain and/or a cell to synthesize the kynurenine hydroxylase so as to obtain the kynurenine hydroxylase and/or quinolinic acid, and mixing the kynurenine hydroxylase and/or quinolinic acid with pharmaceutically acceptable auxiliary materials to prepare the anti-I type herpes simplex virus medicament.

8. The method of claim 7, wherein the gene expression vector comprises at least one copy of a kynurenine hydroxylase gene;

preferably, the engineered strain comprises proeukaryotic and/or prokaryotic cells;

preferably, the eukaryotic cell comprises any one or a combination of two or more of a yeast cell, a mammalian cell, an insect cell or a plant cell;

preferably, the prokaryote comprises escherichia coli.

9. Use of an anti-herpes simplex i virus medicament as claimed in any of claims 1 to 6 for the study of the pathogenesis of herpes simplex i virus.

10. An interferon inducer, comprising: any one or combination of at least two of kynurenine hydroxylase genes, kynurenine hydroxylase enzymes or a metabolite quinolinic acid of the kynurenine hydroxylase enzymes;

preferably, the interferon inducer is targeted to type I interferon.